Therapies for Children With Autism Spectrum Disorders

Evidence Table. Therapies for children with ASD (continued)
Study
Inclusion/ Exclusion
Description Intervention
Criteria/ Population
G1a: 9/52 (17.3)
G1b: 14/59 (23.7)
G1c: 10/54 (18.5)
G2: 11/51 (21.6)
Aripiprazole:
G1a: 1/52 (1.9)
G1b: 1/59 (1.7)
G1c: 2/54 (3.7)
G2: 3/51 (5.9)
Anxiolytic:
G1a: 8/52 (15.4)
G1b: 9/59 (15.3)
G1c: 10/54 (18.5)
G2: 8/51 (15.7)
Antidepressant:
G1a: 8/52 (15.4)
G1b: 6/59 (10.2)
G1c: 13/54 (24.1)
G2: 3/51 (5.9)
Psychostimulant:
G1a: 3/52 (5.8)
G1b: 11/59 (18.6)
G1c: 7/54 (13.0)
G2: 5/51 (9.8)
Marcus et al.,
2009
(continued)
C-70
Baseline
Measures Outcomes
G1c: -3.2 (0.5)
(n=53)
G2: -1.7 (0.5)
(n=48)
G1a/G2: P = NS
G1b/G2: P = NS
G1c/G2: P ≤ 0.05
Other:
Pediatric QoL
Inventory
combined scales
total score, LSQ
treatment
difference (95%
CI):
G1a: NR (NS)
G1b: NR (NS)
G1c: 8.2 (1.2-
15.2)
Harms:
Experienced ≥ 1
harm, safety
sample, n (%)
G1a: 46/52 (88.5)
G1b: 53/59 (89.8)
G1c: 46/54 (85.2)
G2: 37/51 (75.5)
Harms (incidence
≥ 5% in G1a, G1b
or G1c and twice
G2 rate), n (%):
Sedation:
G1a: 9 (17.3)
G1b: 17 (28.8)
G1c: 13 (24.1)
G2: 3 (5.9)
Tremor:
G1a: 4 (7.7)
G1b: 7 (11.9)
G1c: 6 (11.1)
G2: 0
Somnolence:
G1a: 4 (7.7)
G1b: 5 (8.5)
G1c: 5 (9.3)
G2: 2 (3.9)
Drooling:
G1a: 2 (3.8)
G1b: 8 (13.6)
G1c: 5 (9.3)
G2: 0
Headache:
G1a: 3 (5.8)
G1b: 5 (8.5)
G1c: 5 (9.3)
G2: 2 (3.9)
Extrapyramidal